Drugs / Helixor® M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03051477 | Mar 2017 → Jan 2021 | neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Helixor M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03051477 ↗ |
| Route | Intravenous | “3-hour IV infusion on Monday, Wednesday, and Friday of each week.” NCT03051477 ↗ |